Pharma Valley News | Globalization Accelerates as Zhang Jiang Pharma Valley Enterprises Achieve Key Milestones

Zhang Jiang Pharma Valley companies continue to strengthen their product competitiveness and overseas channel capabilities, earning recognition from institutions both at home and abroad.

MicroPort Robotics' Toumai® Surgical Robot Surpasses 300 Global Commercial Orders

On June 16, MicroPort Robotics, a Zhang Jiang Pharma Valley enterprise, announced that its self-developed Toumai® surgical robot has officially surpassed 300 global commercial orders, making it one of the top two laparoscopic surgical robots worldwide to achieve large-scale international commercial deployment.

New orders in the first half of 2026 have already exceeded the total for the entire previous year, significantly outpacing other domestic surgical robot makers in the global commercialization race.

The Toumai® system has gained market access in more than 100 countries and regions, spanning Asia, Europe, Latin America, Oceania, and Africa — establishing a comprehensive global regulatory approval framework.

To meet surging demand across the surgical robotics market, MicroPort Robotics has built a full-chain, multi-tiered supply chain covering precision components, specialized consumables, core modules, and system integration. The company has formed robust capabilities in research and development, manufacturing, and delivery.

The Toumai® robot and other commercially launched products, along with their accompanying consumables, have all achieved large-scale production, with an overall annual production capacity of 500 units — providing a solid foundation for continued global commercial expansion and installation growth.

Mabwell's Nectin-4 ADC 9MW2821 Presents Two Clinical Results at ESMO Gynae 2026

Mabwell (Shanghai) Bioscience Co., Ltd., another Zhang Jiang Pharma Valley company, announced that two latest clinical results for its self-developed Nectin-4 targeted antibody-drug conjugate 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer were presented at the 2026 European Society for Medical Oncology Gynaecological Cancers Annual Congress (ESMO Gynae 2026), held June 17–19 in Copenhagen, Denmark.

The two studies demonstrated that 9MW2821 exhibits a manageable safety profile and encouraging therapeutic activity in cervical cancer patients. Notably, a trend toward exceptionally prolonged survival benefit was observed in patients previously treated with immunotherapy. Meanwhile, the combination of 9MW2821 with a PD-1 inhibitor in advanced cervical cancer showed remarkable anti-tumor activity.

Professor Yang Huijuan of Fudan University Shanghai Cancer Center presented the findings on behalf of the research team.

9MW2821 is an innovative Nectin-4 targeted ADC independently developed by Mabwell based on its proprietary ADC development platform. The company is pursuing multiple ADC-plus-immunotherapy combinations. It is the world's first Nectin-4 ADC to enter Phase III clinical trials for both cervical cancer (CC) and triple-negative breast cancer (TNBC) indications.

The drug candidate has launched four Phase III pivotal registration trials. Three indications have received FDA Fast Track designation, one indication has been granted Orphan Drug designation, and two indications have been included in the Center for Drug Evaluation (CDE) Breakthrough Therapy designation list.

UniXell's UX-DA003 Receives FDA IND Clearance

On June 19, UniXell Biotechnology, a Zhang Jiang Pharma Valley enterprise, announced that UX-DA003 — an allogeneic iPSC-derived midbrain dopaminergic neural progenitor cell injection — has received implicit clinical trial approval from the U.S. Food and Drug Administration (FDA).

This marks another key milestone in UniXell's internationalization journey, following the product's National Medical Products Administration (NMPA) clinical trial approval on June 3, 2026.

With the FDA clearance for UX-DA003, UniXell has become one of the few companies globally to master both autologous and allogeneic iPSC cell therapy technologies for Parkinson's disease, building a differentiated product portfolio for distinct patient populations:

Autologous Path (UX-DA001): Using the patient's own cells, this approach completely eliminates the risk of immune rejection. The product is currently undergoing a Phase I clinical trial at Shanghai Ruijin Hospital. The first patient has been treated for over one year, with clinical data showing good safety and significant efficacy — the patient has regained the ability to live independently. In June 2025, UX-DA001 received FDA Fast Track designation.

Allogeneic Path (UX-DA003): Leveraging a universal iPSC seed cell bank, this approach enables large-scale manufacturing. Preclinical studies have shown that UX-DA003 can significantly improve motor deficits in Parkinson's disease animal models and precisely integrate into host brain circuits to form functional connections, offering new hope for patients in urgent need of treatment.

Minwei Bio's Dual-Target siRNA Enters Phase I Trial in Australia

Minwei Bio, yet another Zhang Jiang Pharma Valley company, announced that its innovative dual-target small interfering RNA (siRNA) drug MWX205 injection has formally submitted a Phase I clinical trial application to the Human Research Ethics Committee (HREC) in Australia and received approval.

The program aims to simultaneously inhibit two key targets — PCSK9 and ANGPTL3 — to provide a more potent and longer-lasting lipid-lowering solution for patients with hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD).

MWX205 is currently the world's first PCSK9/ANGPTL3 dual-target siRNA to enter the clinical stage, marking Shanghai Minwei Bio's entry into the dual-target siRNA era in the metabolic and cardiovascular therapeutic field.

Compiled from: Medical Notes and official company announcements